BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $15.57.

BCRX has been the topic of several analyst reports. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Needham & Company LLC raised their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after buying an additional 1,583,826 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after purchasing an additional 481,359 shares in the last quarter. Caligan Partners LP boosted its holdings in BioCryst Pharmaceuticals by 16.0% during the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock worth $22,529,000 after purchasing an additional 412,347 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after purchasing an additional 318,800 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.69 on Friday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -12.61 and a beta of 1.85. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50. The business’s fifty day moving average price is $8.12 and its two-hundred day moving average price is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period last year, the firm posted $0.28 EPS. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.